Streetbeat News

SGPYY

Sage Group plc

http://www.sage.com/

CEO

Stephen Hare

Open

65.71

Mkt cap

16B

Volume

2.3K

High

65.71

P/E Ratio

40.84

52-wk high

66.14

Low

64.76

Div yield

0.02

52-wk low

49.22

The Sage Group plc held its Q4 2024 earnings call, discussing its full-year results. Key participants included CEO Steve Hare and CFO Jonathan Howell, with analysts from major financial institutions attending.

Portfolio Pulse from

November 23, 2024 | 1:15 am

AssetMark has integrated TIFIN Sage's AI-driven technology into its wealth management platform to provide personalized solutions for financial advisors.

Portfolio Pulse from

November 21, 2024 | 1:45 pm

Sage Therapeutics announced disappointing results from its Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) for cognitive impairment in Huntington's Disease patients. This follows a previous failure in an Alzheimer's study.

Portfolio Pulse from

November 20, 2024 | 4:00 pm

Sage Therapeutics has decided to terminate its trial for the therapy dalzanemdor in treating Huntington's disease after it failed to meet its goals. This marks the third failure for the therapy, which also did not succeed in trials for Alzheimer's disease.

Portfolio Pulse from

November 20, 2024 | 1:00 pm

Sage Therapeutics has decided to halt the development of its experimental drug for treating cognitive impairment in Huntington's disease patients after it failed a mid-stage study.

Portfolio Pulse from

November 20, 2024 | 12:15 pm

Sage Group PLC shares surged 17% after reporting improved profit margins and announcing a £400 million share buyback. Revenue grew 7% to £2.3 billion, with underlying revenue up 9.3% and organic recurring revenue up 11%, aligning with analyst expectations.

Portfolio Pulse from

November 20, 2024 | 9:00 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.